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ABSTRACT 
A recent meeting was held on March 22, 2019, among the U.S. Food and Drug Administration 
(FDA), clinical scientists, pharmaceutical and biotech companies, clinical trials cooperative 
groups, and patient advocacy groups to discuss challenges and potential solutions for increasing 
development of therapeutics for central nervous system (CNS) metastases. A key issue identified 
at this meeting was the need for consistent tumor measurement for reliable tumor response 
assessment, including the first step of standardized image acquisition with an MRI protocol that 
could be implemented in multicenter studies aimed at testing new therapeutics. This document 
builds upon previous consensus recommendations for a standardized brain tumor imaging 
protocol (BTIP) in high-grade gliomas and defines a protocol for brain metastases (BTIP-BM) 
that addresses unique challenges associated with assessment of CNS metastases. The “minimum 
standard” recommended pulse sequences include: 1) parameter matched pre- and post-contrast 
inversion-recovery (IR)-prepared, isotropic 3D T1-weighted gradient echo (IR-GRE); 2) axial 
2D T2-weighted turbo spin echo acquired after gadolinium-based contrast agent (GBCA) 
injection and before post-contrast 3D T1-weighted images; 3) axial 2D or 3D T2-weighted 
FLAIR; 4) axial 2D, 3-directional diffusion-weighted images; and 5) post-contrast 2D T1-
weighted spin echo images for increased lesion conspicuity. Recommended sequence parameters 
are provided for both 1.5T and 3T MR systems. An “ideal” protocol is also provided, which 
replaces IR-GRE with 3D TSE T1-weighted imaging pre- and post-gadolinium, is best 
performed at 3T, and for which DSC perfusion is included. Recommended DSC perfusion 
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Key points: Brain metastases present unique imaging challenges. Standardized imaging protocols 
are needed for clinical trials. We provide evidence-based and consensus-driven standardized 
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MANUSCRIPT BODY 
Need for Development of Therapeutics for Treating Brain Metastases 
Brain metastases are the most common central nervous system (CNS) tumor,1,2 with more than 
150,000-200,000 new patients diagnosed with brain metastases each year in the U.S.3,4 This 
incidence is substantially greater than that of primary malignant brain tumors.5 The lifetime 
incidence of brain metastases among all cancer patients is approximately 10-30%.2,6,7 The most 
common primary tumors are lung cancer, breast cancer, and melanoma, occurring in 
approximately 40-50%, 15-20%, and 5-20% of newly diagnosed brain metastasis patients, 
respectively,8 with melanoma having the highest predilection to metastasize to the brain 
(~50%).9,10 The incidence of brain metastases appears to be increasing, in part due to an overall 
increase in primary cancers, as well as better systemic therapies which increase the probability of 
metastatic disease as patients live longer, especially within the brain as a potential sanctuary 
protected by the blood brain barrier.2    
 
The discovery of brain metastases has always been very sobering, indicating disseminated 
malignancy and historically a dismal prognosis. However, hope is increasing at the dawn of the 
molecular and immunotherapeutic era, with improved local therapies such as stereotactic 
radiosurgery (SRS) and earlier detection of brain metastases while patients have good 
performance status.11,12 Improvements in outcome for patients with brain metastases from lung 
cancer, breast cancer, and melanoma, have all been reported, and for certain patient subsets, 
survival is substantially longer than historical estimates. For instance, the success of monoclonal 
antibodies against immune checkpoints in some cases of advanced melanoma and NSCLC13-15 
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targeted agents, including BRAF inhibitors in melanoma and other cancers, ALK inhibitors in 
ALK+ NSCLC, and HER2 inhibitors in HER2+ breast cancer.16-18 Other clinical trials for CNS 
metastases with newer targeted therapies (e.g. NCT03994796) and multiple immunotherapies are 
currently in progress (e.g. NCT02886585, NCT02939300). Use of SRS for multiple brain 
metastases is also rising, particularly following the results of the Alliance N057419 and N107C20 
trials with greater community healthcare penetrance of SRS. That being said, it is clear that much 
work still needs to be done, as prognosis following the diagnosis of brain metastasis is still often 
enumerated in months,3,21,22 underscoring the need for continued development of therapeutic 
options for patients with brain metastases. 
 
Need for Imaging Standardization for Improved Therapeutic Response Assessment in 
Brain Metastases 
With new efforts at treating brain metastases in an era when the vast majority of patients are 
diagnosed and monitored using MR imaging, reliable methods for disease monitoring and 
response assessment using MR imaging data are needed. Particularly in the conduct of clinical 
trials, implementation of standardized brain MRI protocols is an essential first step towards 
achieving consistent measurement and reliable assessment of response to novel therapies, 
whether response is assessed using clinical response criteria or automated approaches. Such a 
standardized brain tumor imaging protocol (BTIP) has already been developed23 for gliomas and 
is being widely adopted in glioma trials. Based on the experiences of implementing the BTIP 
protocol, it has become apparent that MRI protocols for clinical trials must generally also serve 
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minimize duplicative imaging sessions for patients and in order to avoid challenges with 
reimbursement. 
 
A recent meeting was held on March 22, 2019, among the U.S. Food and Drug Administration 
(FDA), clinical scientists, pharmaceutical and biotech companies, clinical trials cooperative 
groups, and patient advocacy groups to discuss challenges and potential solutions for increasing 
the development of therapeutics for CNS metastases. At this meeting, the need for more 
consistent response assessment methodology for brain metastases was identified as a key issue, 
and the first step towards consistent, reliable response assessment is the standardization of image 
acquisition with an MRI protocol that could be implemented in the multicenter setting.   
 
The multidisciplinary and multinational RANO brain metastases (RANO-BM) working group 
has developed standardized guidelines for determining response to therapy for brain 
metastases.24-26 This group has provided a consensus approach to measuring brain metastases and 
incorporating corticosteroid dosing and clinical status into the response assessment criteria.24 The 
difficult issues of response assessment following stereotactic radiosurgery and immunotherapy 
were also broached by this group; they stated that advanced imaging may assist in discriminating 
tumor progression from treatment effect in these post-treatment circumstances while 
acknowledging that to date, these advanced imaging techniques have not shown robust validation 
to justify the recommendation of any particular advanced imaging technique(s) for this 
purpose.24 Finally, a supplementary appendix to the RANO-BM manuscript24 gives a 
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However, particularly as clinical trials for brain metastases increase, and MRI technology 
evolves, an updated minimum recommended protocol for imaging brain metastases in clinical 
trials is needed. In this current effort, we use the RANO-BM appendix24 and the similar BTIP23 
as a core of such a revised protocol, which we hope will provide meaningful and generalizable 
imaging data from clinical trials and which may also facilitate standard of care clinical 
evaluation and decision-making.   
 
Magnetic Resonance Imaging of Brain Metastases 
The early detection of brain metastases leads to earlier interventions and has been shown to 
result in better quality of life.27,28 Treatment strategies (e.g. stereotactic radiosurgery vs. whole 
brain radiation) are often based on the number and size of metastases,29 and thus accurate 
imaging of brain metastases is crucial. Multiple brain metastases are common with many primary 
tumor histologies, though solitary metastases may be seen with some cancers.30,31 Brain 
metastases are distributed proportional to blood flow, with 80% in the cerebral hemispheres, 
15% in cerebellum, and 5% in the brainstem.32,33 Brain metastases commonly occur at the 
interface between gray and white matter, possibly due to the change in size of arterioles from 
cortex to white matter.34 However, they also occur purely within white matter as well as within 
cortex and deep gray matter structures.  
 
The diagnosis of brain metastases is typically made with gadolinium-based contrast-enhanced 
MRI, which is superior to contrast-enhanced CT.35-38 Prior to 2006, treatment guidelines for 
brain metastases were based upon studies in which metastases were diagnosed and monitored 
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for the detection of brain metastases has been well documented for more than 30 years.42-46 
Almost all brain metastases enhance in their entirety, due to the lack of blood-brain and blood-
tumor barriers,34 unless the tumors have non-enhancing cystic or frankly hemorrhagic 
components. Brain metastases of moderate to large size are typically surrounded by substantial 
vasogenic edema, either related to increased tumor capillary permeability and/or temporary 
vascular occlusion from neoplastic cell growth after hematological spread.34 Small metastases 
can also present with disproportionate peritumoral edema. T2-weighted imaging and T2-
weighted FLAIR best detect the T2 prolongation associated with this edema in the brain. 
Metastases themselves vary in signal intensity on T2-weighted imaging, and while usually 
relatively hyperintense34 may be hypointense, classically associated with highly cellular 
neoplasms with high nuclear-to-cytoplasm ratios and with some, though not all, adenocarcinoma 
metastases.34,47-49 Calcified metastases are rare but possible. Metastases vary in apparent 
diffusion coefficient (ADC) and appearance on diffusion-weighted imaging (DWI), and attempts 
have been made to correlate ADC with tumor histology and response to therapy such as SRS 
with limited success.50-52 
 
Baseline MR Evaluation  
For response assessment using the current standardized response criteria, brain metastases must 
be accurately measurable in at least one dimension.24 Thin-section, preferably volumetric, T1-
weighted imaging would be most desirable. Identical pre- and post-contrast T1-weighted 
imaging allows the subtraction of inherent T1 shortening or bright signal which may be seen in 
hemorrhage (methemoglobin) from true contrast enhancement, which can aid in clinical 
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correlates with certain histologies (being particularly common in melanoma, renal cell 
carcinoma, choriocarcinoma, and thyroid carcinoma but also common in breast and lung 
carcinoma) and with increasing size. Overall, approximately 20% of metastases may be overtly 
hemorrhagic,34,53 with two-thirds of large metastases showing evidence of hemorrhage on 
susceptibility weighted imaging (SWI).54 Additionally, melanoma metastases can have T1 
shortening from melanin. Therefore, a means to account for pre-contrast T1 hyperintensity in 
evaluating contrast enhancement is important. Pre- and post-contrast image subtraction also 
markedly improves contrast ratios of enhancing lesions.55 
 
Improved Detection of Brain Metastases 
The question of which post-contrast T1-weighted pulse sequence is “best” is complicated. The 
first limitations in answering this question relate to what MR scanner hardware and software a 
particular site possesses, including field strength (usually 1.5T vs. 3T). 3T brain MRI offers 
signal-to-noise ratio (SNR) advantages over 1.5T, which can be traded off for better spatial 
resolution or decreased imaging time.56-58 Any disadvantages of 3T are probably offset by its 
advantages when imaging brain metastases.59,60 For instance, 3D FSE T1-weighted techniques 
such as CUBE (GE Healthcare), SPACE (Sampling Perfection with Application optimized 
Contrasts by using different flip angle Evolutions; Siemens Healthcare) or VISTA (Volumetric 
Isotropic TSE Acquisition; Philips Healthcare),61 are all improved in SNR at 3T compared to 
1.5T.   
 
Magnetization prepared (“IR-prepped”) 3D gradient echo (GRE) pulse sequences such as MP-
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pulse sequences with exquisite anatomical depiction, which are very widely available in 
community and academic imaging centers at both 1.5T and 3T field strengths. They form the 
backbone of the BTIP protocol23 and are featured in the minimum standard protocol for brain 
metastases recommended in this publication. As these are 3D series, orthogonal reformats can 
and should be created from them, and image review should be performed in axial, sagittal, and 
coronal planes. However, there are disadvantages of post-contrast IR-GRE pulse sequences. The 
contrast enhancement of brain lesions is slightly less conspicuous with spoiled GRE-based pulse 
sequences than with SE-based pulse sequences.62,63 The relatively bright white matter of IR-GRE 
yields good gray-white differentiation and depiction of anatomy, but a brightly enhancing 
metastasis on bright white matter then becomes less conspicuous, having a lower contrast ratio 
(Figure 1). In comparison, SE-based pulse sequences including the 3D turbo SE (TSE) T1-
weighted SPACE/CUBE/VISTA have relatively lower signal intensity in white matter, in part 
due to magnetization transfer effects,64 increasing the contrast ratio of enhancing metastases 
within white matter (Figure 1). Indeed, Knauth et al. reported equivalent enhancing lesion 
conspicuity relative to white matter using magnetization transfer (by applying an off-resonance 
radiofrequency pulse to suppress background tissue signal) SE T1-weighted imaging and a single 
dose of gadolinium, when compared to no magnetization transfer and triple dose gadolinium.65 
IR-GRE pulse sequences with “bright blood” contrast also make normal cortical vessels much 
more prominent than with SE-based pulse sequences, which have greater inherent flow 
suppression. (3D turbo SE sequences like SPACE or CUBE have inherent flow suppression 
based on two mechanisms: 1) uncompensated gradient moments in the echo train which 
introduce intravoxel dephasing, and 2) stimulated echoes from non-180° variable flip angles 
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bright dots, which can hinder the distinction of peripheral subcentimeter enhancing metastases, 
despite relatively high lesion SNR. Lastly, unlike with SE-based pulse sequences, it is not 
feasible to fat saturate IR-GRE pulse sequences, and so enhancing osseous metastases may be 
indistinguishable within the normally fat containing, T1-bright skull, skull base and upper 
cervical vertebral marrow.  
 
Previous studies found superior detection of brain metastasis with 3D FSPGR or MPRAGE (with 
1-1.4 mm slice thickness) when compared to thick section (6-7 mm) 2D SE imaging.63,66,67 
However, a 2016 metaanalysis68 which included five studies64,69-72 comparing 3D TSE T1 (e.g. 
SPACE) and 3D MPRAGE with equal slice thickness (1 mm) found superior detection of small 
metastases with 3D TSE, although these five studies were performed at 3T field strength only. 
These results are supported by other published data. Chappell et al. demonstrated greater post-
contrast lesion conspicuity with SE compared to GRE imaging.73 Majigsuren et al. found higher 
contrast-to-noise ratio (CNR) within a sampling of various brain tumors with T1-weighted 
CUBE (3D TSE) when compared to 3D FSPGR at 3T, despite performing the post-contrast 
CUBE prior to the FSPGR in all instances.74 Kammer et al. reported significantly higher 
detectability of contrast enhancing brain tumors with 3D TSE compared with MPRAGE at 3T 
with regards to number of lesions identified (particularly if small) as well as superiority of 3D 
TSE with regards to CNR and diagnostic confidence.75 Danieli et al. reported higher contrast 
rate, CNR, and visual conspicuity among metastases and gliomas with SPACE and VIBE 
relative to MPRAGE, and more accurate size and morphology estimates with SPACE in a 3T 
study.76 Kim et al. reported approximately double the detection rates of 5 mm or less brain 
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MPRAGE as well as higher CNR of metastases and shorter reading time with DANTE SPACE.77 
Similar to 2D TSE, 3D TSE T1-weighted images can be fat-saturated, an advantage in detecting 
osseous metastases, unlike IR-GRE techniques like MPRAGE and BRAVO. However, 3D TSE 
is more challenging to acquire at 1.5T due to lower SNR. Although more recent iterations of 
1.5T T1-weighted TSE seem to have acceptable SNR and lesion conspicuity, published literature 
for detection of brain metastases is currently still lacking. 3D TSE also may not have been a 
stock MRI pulse sequence with relatively older scanner purchases, and therefore, imaging 
centers may require an additional cost to install the sequence. It is also not standardized among 
MR vendors. There is not a motion-compensated version of 3D TSE, which is therefore 
susceptible to motion artifacts. Additionally, 3D TSE cannot be used with metallic SRS 
immobilization frames because eddy currents arise in the frame due to the long echo trains; GRE 
pulse sequences are therefore used for SRS targeting.78  
 
It is also important to recognize in this discussion of ideal post-contrast T1-weighted imaging 
that much of the published data concerns itself with the issue of metastasis detection rather than 
measurement. Published data on variability of measurements of brain metastases is limited.79 
 
In summary, for post-contrast T1-weighted imaging, the universal availability of IR-GRE pulse 
sequences and their many strengths support their use in a standardized brain metastasis imaging 
protocol, but their limitations in identifying small metastases and osseous metastases promote the 
recommendation that sites also include an SE or TSE post-gadolinium T1-weighted pulse 
sequence, with fat suppression where possible to aid in identifying osseous metastases. The ideal 
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should also be fat-saturated for better evaluation of osseous metastases, if available. (This 
sequence would effectively replace the 3D T1-weighted IR-GRE sequence). If not available, an 
axial and/or coronal or 3D T1-weighted FLAIR could be considered at 3T,55,80-82 where the 
inversion pulse helps null CSF at 3T. At 1.5T, adding an axial and/or coronal T1-weighted SE 
series may increase accuracy and diagnostic confidence for small brain metastases. 
Disadvantages of T1-weighted SE imaging to keep in mind include ghosting artifacts due to 
strong signal enhancement in flowing blood, especially in the posterior fossa from the dural 
venous sinuses, and thicker image slices.  
 
Other considerations for the detection of small metastases include the choice of gadolinium-
based contrast agent (GBCA), its dose, and the timing of imaging following IV administration. 
High relaxivity (r1) GBCA,83-87 double- or triple-dose GBCA,88-97 or increased delay time, 
particularly with IR-GRE pulse sequences,89,98,99 may lead to greater sensitivity for small 
metastases. However, some concern over gadolinium deposition in the body100 and nephrogenic 
systemic fibrosis101 has led to constraints in GBCA dosing at some local institutions, and so we 
provide a protocol using single-dose GBCA administration. Since delayed imaging after GBCA 
administration is not practical for many institutions, we do not give a uniform recommendation 
for an additional delay after IV administration of GBCA other than that introduced by 
performance of T2-weighted and – optional – dynamic susceptibility contrast (DSC) perfusion-
weighted MRI after GBCA administration and before post-contrast T1-weighted imaging. The 
time interval between GBCA administration and post-contrast T1-weighted imaging can impact 
lesion conspicuity and apparent lesion size,89,102 and should therefore be standardized. In our 
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T2-weighted imaging between IV GBCA administration and post-contrast 3D T1-weighted 
imaging. 
 
Finally, in post-processing or live image review, clinicians may also benefit from reviewing 3D 
post-contrast T1-weighted image sets with overlapping maximum intensity projections (MIPs, 
e.g. 10 mm sections reconstructed at 4 mm intervals), which may help with accuracy and speed 
of image review for small metastases.103 
 
When evaluating for osseous metastases, fat-saturated T2-weighted and T2-weighted FLAIR 
images, at least one post-contrast T1-weighted series, and DWI are helpful. Leptomeningeal 
metastases may be better evaluated with post-contrast T2-weighted FLAIR than some post-
contrast T1-weighted imaging,104 which though not included in this basic protocol, could be 
added for suspected or known leptomeningeal metastasis. Post-contrast 3D TSE T1-weighted 
imaging with its relative vascular signal suppression is also useful for leptomeningeal metastasis 
detection.105 We also refer the reader to the RANO Leptomeningeal Response Assessment 
group’s recommendations for leptomeningeal metastasis.106,107 
 
Stereotactic Radiosurgery and Radiation Necrosis 
Many brain metastases are now treated with stereotactic radiosurgery (SRS), and many if not all 
clinical trials for brain metastases allow for SRS. This introduces the particular challenge of 
response assessment for enlarging, contrast-enhancing lesions following SRS.108,109 
Approximately one-third of treated metastases will increase in size on contrast-enhanced MRI 
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necrosis is not uncommon following SRS. This translates to roughly half of SRS-treated patients 
experiencing an enlarging contrast-enhancing lesion.110 The incidence of radiation 
injury/necrosis depends upon the radiation dose utilized, the volume of the target lesion, and the 
means by which radiation necrosis is determined, but has been estimated at 6-26%.21,111 
However, it has been estimated as high as 60% cumulative risk for larger lesions111 and may also 
be higher for patients also treated with immunotherapy.112 Radiation necrosis typically occurs 3-
18 months after SRS but can occur up to three years post-SRS.21 However, conventional MRI 
poorly differentiates between radiation necrosis and tumor or an admixture of the two,113,114 and 
alternative methods using tumor segmentation115 or delayed imaging116 are time-intensive and 
may be difficult to routinely employ in clinical care. Admixture of tumor and necrosis is not 
uncommon following SRS109 and further complicates diagnosis. 
 
Investigators have pursued “advanced” or physiologic / mechanistic MRI techniques, as well as 
other imaging modalities such as PET, to help discriminate between radiation necrosis and 
recurrent tumor. DWI and ADC,117-119 MR spectroscopy,120,121 arterial spin labeling (ASL),122 
dynamic contrast-enhanced (DCE) MRI,119,123-125 and DSC-MRI119,126-128 have all been evaluated 
in this clinical context, as have 201thallium SPECT,122,129 18F-FDG PET, and amino acid PET 
(11C-methionine, 18F-fluorodopa, 18F-fluoro-ethyltyrosine, 18F-fluorocholine).130-138 Each of these 
techniques has some merit as well as unique challenges. None has been validated in multicenter 
trials of brain metastases treated with SRS. Some of these techniques also produce findings 
which may predictably evolve over time following SRS, complicating their interpretation.139 
Amino acid PET, with its low background activity in the brain, has particular promise for 
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not generally reimbursable in the United States, which makes it difficult to universally 
recommend. However, for trials involving other parts of the world such as Europe for which 
amino acid PET may be more feasible, it should certainly be considered for response assessment 
post-SRS.140 Delayed contrast extravasation MRI with TRAMs (treatment response assessment 
maps) has also been used and shows promise,116,141,142 including with T1 mapping and 
subtraction,143 though this requires scanning at both 5 minutes and again at 60-105 minutes after 
IV GBCA administration. This may not be practical for a protocol standardized for use across 
many institutions and requires specific software for its analysis, but investigators could consider 
this if it is feasible for their sites. Future means of imaging discrimination of radiation necrosis 
and viable tumor could include texture analysis144 and deep learning145. 
 
DWI is included in the standardized protocols, as it was for the BTIP protocol,23 for a few 
reasons. It is often included in any brain MRI, given the unique information it provides with 
regards to unanticipated pathology such as infarction or abscess. It can suggest tumor cellularity. 
It is a very fast pulse sequence, requiring only on the order of a minute of MR gradient time, and 
so it does not cost much to perform. Last, as DWI has been117-119 and will likely continue to be 
used in clinical investigations of brain tumor response assessment, we provide it for investigators 
in the standardized protocols.  
 
We encourage the use of DSC-MRI (which requires an IV bolus administration of GBCA) in the 
standardized brain metastasis imaging protocol because it may help differentiate tumor 
progression, characterized by higher blood volume and lower percentage signal recovery, from 
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validation of DSC-MRI for this purpose in multicenter trials, we encourage investigators to 
decide whether or not to mandate DSC-MRI within their own clinical trial contexts. DSC-MRI is 
widely available, technically robust, relatively short in acquisition time (typically on the order of 
2-3 minutes), and requires no additional GBCA beyond that given for conventional post-contrast 
imaging. DSC-MRI requires less MRI gradient time and has substantially higher signal to noise 
than DCE-MRI, making it easier for a wide variety of imaging sites to perform. Based on recent 
computer simulations and in vivo studies, it has been suggested that DSC-MRI using a single-
dose bolus of GBCA without preload, in combination with a low (e.g. 30 degrees) flip-angle and 
post-processing leakage correction which mitigates the effect of GBCA extravasation in contrast-
enhancing tumors, is an efficacious DSC-MRI protocol requiring only a single dose of 
GBCA.146-148 This would be advantageous given that concerns about nephrogenic systemic 
fibrosis101 and gadolinium deposition in other tissues including the brain100 have made some 
centers reluctant to use supra-standard (i.e. >0.1 mmol/kg) doses of gadolinium. Importantly, 
particularly for studies which may perform quantitative analysis of DSC-MRI, parallel imaging 
is advised with DSC-MRI to minimize distortion. 
 
Interpretation of DSC-MRI for brain metastases post-SRS is beyond the scope of this effort, but 
suffice it to say that it should be used with caution and some skepticism in clinical practice. 
Indeed, published data in this setting are limited to single-institution studies; its implementation 
and analysis is very technique-dependent,149 and the timing of DSC relative to SRS and trends in 
DSC metrics over time probably matter. Generally speaking, increased blood volume and 
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necrosis.126-128 We do note that smaller lesions and peripherally located lesions near higher 
baseline cortical perfusion and cortical vessels are more difficult to evaluate with DSC perfusion. 
 
Immunotherapy and Brain Metastasis Imaging 
Immunotherapy has had remarkable success in different settings, including recent clinical trials 
demonstrating promising response rates in brain metastases from melanoma, increasing its 
investigation across brain metastases from many histologies. Because it purposefully stimulates a 
host immune reaction against tumor, it can create “pseudoprogressive” contrast enhancement due 
to inflammatory response rather than recurrent metastases. This creates a challenge for response 
assessment, which has been addressed by the Immunotherapy Response Assessment in Neuro-
Oncology (iRANO) criteria.150 In summary, if radiologic progression is seen within six months 
of immunotherapy, it is advised that patients remain on immunotherapy (if no clinical 
contraindication) for three months, at which time repeat imaging can be used to judge whether 
this represents true progressive disease.150 Research into whether advanced imaging techniques 




The recommended MRI protocol for use in evaluating brain metastases is highly dependent on 
the scanner performance and capabilities at the specific sites. A flowchart to guide decision-
making in terms of the recommended protocol(s) is illustrated in Figure 2. Ideally, if sites are 
able to use a 3T MRI scanner and are able to perform 3D T1-weighted TSE, they should replace 
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Additionally, as a large proportion of patients receive SRS for brain metastases, we encourage 
but do not mandate the inclusion of DSC perfusion MRI as part of a protocol for clinical trials as 
it can provide complementary information to distinguish tumor progression from treatment effect 
in any enlarging contrast-enhancing lesion post-SRS. DSC-MRI is brief, requires no additional 
GBCA, and should be easily acquired at any imaging center. It will not always be helpful in 
distinguishing between tumor progression and radiation necrosis, but sometimes the longitudinal 
changes provided may. We give updated suggestions for DSC-MRI pulse sequence parameters 
as part of the ideal 3T protocol in Table 1. Tables 2 and 3 provide minimum standard 
recommended imaging parameters for evaluation of brain metastases at 3T and 1.5T, 
respectively. These minimum protocols include imaging series that will be familiar to current 
users of the BTIP.  
 
The standard protocol limits GBCA administration to a single-dose (0.1 mmol/kg) bolus, based 
on recent data on DSC-MRI accuracy in the primary brain tumor setting146,147, but we also allow 
for double, 0.2 mmol/kg total GBCA dosing if investigators and sites prefer. If a double dose of 
GBCA is used and DSC perfusion is performed, the first GBCA dose should be used as 
gadolinium preload, preceding the DSC series which would then use the second GBCA dose. A 
higher relaxivity GBCA, for greater lesion contrast conspicuity and possibly improved DSC 
signal change (especially at 1.5T), is preferable but not mandated. 
 
If sites have 3T scanners and if patients have no contraindications to scanning at 3T, we 
recommend acquiring brain imaging at 3T over 1.5T, as the advantages at 3T outweigh 
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detection of small metastases is 3D TSE T1-weighted imaging with greater sensitivity at 3T 
compared to 1.5T. 3D TSE T1-weighted imaging at 1.5T has not been well-evaluated for brain 
metastasis detection, and its quality can vary depending upon scanner platform. Therefore, we 
recommend 3D TSE T1-weighted imaging be used at 3T but cannot universally endorse it at 
1.5T until additional studies are conducted. 
 
For sites not able to perform stand-alone 3D TSE T1-weighted imaging and would use the 
“standard” protocol with 3D IR-GRE instead, we recommend the addition of  one post-contrast 
2D SE or TSE T1-weighted series at the conclusion of the MR exam both for clinical purposes 
and also for trial outcome purposes. This can assist in the detection of small metastases that may 
not be detected on IR-GRE imaging or which may be obscured by artifacts that differ between 
the two post-contrast pulse sequences. For instance, a second post-contrast T1-weighted series 
may increase diagnostic confidence when considering SRS to new very small metastases, or if 
artifacts are present in a particular location on one imaging series. Although we advocate for 
acquisition of this additional sequence, we are not providing specific parameters for the second 
post-contrast T1-weighted series because: 1) we encourage sites to perform their best possible 
pulse sequence, which may vary significantly, and 2) for clinical trial evaluation purposes and 
generalizability, the 3D post-contrast T1-weighted scan should be used for measurements and 
advanced image post-processing, whereas the post-contrast SE or TSE series can be used in a 
qualitative way to support the accuracy of the BTIP based protocol. We recommend that such a 
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Acknowledging that some imaging sites may routinely perform either turbo spin echo T2-
weighted or T2-weighted FLAIR imaging in order to reduce exam time, we recommend 
acquiring both. Current automated segmentation algorithms utilize both T2- and T2-weighted 
FLAIR, which may be important for some trials. However, if sites are only able to acquire one of 
these sequences, primary investigators could consider this as acceptable, although less optimal. 
For instance, primarily cystic metastases may be best appreciated on T2-weighted imaging.   
 
As T2-weighted FLAIR is also performed pre-GBCA administration at some sites, and post-
GBCA administration at others, we also allow for investigators and/or sites to choose this timing 
of T2-weighted FLAIR, simply pointing out that post-contrast T2-weighted FLAIR will depict as 
bright not only lesions with T2 lengthening but also GBCA-enhancing lesions. Advantages of 
performing T2-weighted FLAIR post-gadolinium include the potentially better conspicuity of 
leptomeningeal metastases and some parenchymal metastases. Lastly, it is crucial that at least 
one pulse sequence be performed between the administration of GBCA and the first post-contrast 
T1-weighted series, to optimize lesion contrast enhancement. Typically, T2-weighted imaging is 
performed as this temporal “spacer” since GBCA enhancement is not detectable in non-FLAIR 
T2-weighted images. However, if sites do not perform routine T2-weighted imaging, they will 
need another pulse sequence such as a T2-weighted FLAIR at this time point in the imaging 
protocol. 
 
Some imaging centers routinely perform susceptibility weighted imaging (SWI), which has very 
good sensitivity for paramagnetic substances such as hemosiderin in hemorrhagic tumors and 
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which may have some utility in their evaluation, though SWI alone is not as sensitive for small 
metastases as is post-contrast T1-weighted imaging. Investigators should feel free to include 
SWI or allow it if desired; its only downside is that it requires MR gradient time on the order of 
five minutes. 
 
It is strongly encouraged that imaging centers employ the same MRI scanner platform, including 
field strength, and the same imaging protocol, at all scan time points for any given patient. This 
will aid in accurately evaluating imaging changes over time. A cautionary note for clinical 
investigators is warranted here. The clear advantages to the “ideal” protocol over the “minimum 
standard” protocol justify it being used whenever possible, and its inclusion in this document 
could serve to also better inform sites when they are upgrading their MRI equipment. However, 
because many sites will not be able to perform the “ideal” protocol or may have only a single or 
limited number of capable scanners, this could present a challenge to performing follow-up MR 
exams on a given patient on the same scanner platform. This underscores the need for clear 
communication and cooperation with radiology departments or imaging centers. 
 
The aforementioned protocol is meant to provide a fundamental standard for use in clinical trials 
involving brain metastases. Sites are welcome to add additional pulse sequences to meet their 
particular clinical needs. For example, some sites may feel more comfortable always acquiring a 
second, confirmatory post-contrast T1-weighted sequence for greater certainty in identifying 
small metastases, particularly if there are artifacts. Also, sites may consider adding other imaging 
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weighted imaging, ASL, DCE, MR spectroscopy, or PET for better differentiation of radiation 
necrosis and recurrent tumor in the post-SRS setting.  
 
Conclusion 
Brain metastases present some unique imaging challenges when compared to gliomas. We 
therefore provide suggestions for a “minimum standard” as well as  “ideal” MR imaging 
protocols, depending on imaging sites’ capabilities, that should serve well for clinical purposes 
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Figure Legends:  
Fig. 1: Comparison of 3D IR-GRE (A, C) and 3D TSE (B, D) T1-weighted imaging in a 
patient with metastatic lung carcinoma to the brain. Larger lesions (e.g. right posterior frontal, 
white arrows, A and B) are well visualized with both techniques. Smaller lesions (e.g. right 
posterior temporal, black arrows, C and D) may be better visualized with 3D TSE T1-weighted 
imaging due to more native vascular signal suppression and higher contrast:noise ratio relative to 
underlying brain. 
 
Fig. 2: Metastatic Brain Tumor Imaging Protocol Decision-Making Flow Chart. If sites are 
using a 3T MRI scanner and have 3D TSE available they should use Table 1 (Ideal 
Recommended 3T Protocol). If sites are using a 3T MRI scanner and do not have 3D TSE they 
should use Table 2 (Minimum Standard 3T Protocol). If sites use a 1.5T scanner they should use 
Table 3 (Minimum Standard 1.5T Protocol). Note that DSC perfusion may be used with the 






Table 1: “Ideal” Recommended 3T Metastatic Brain Tumor Imaging Protocol 
 


























3D T1w TSE 
Postb 
Sequence TSEs TSEc,s SS-EPIg GE-EPI TSEc,s TSEs 
Plane Sagittal or 
Axial 
Axial Axial Axial Axial Sagittal or 
Axial 
Mode 3D 2D 2D 2D 2D 3D 
TR [ms] 550-750 >6000 >5000 1000-
1500 
>2500 550-750 
TE [ms] Min 100-140 Min 25-35ms 80-120 Min 
TI [ms]  2000-2500k     
Flip Angle Defaultt 90º/≥160º 90º/180º 30º 90º/≥160º Defaultt 
Frequency 256 ≥256 128 ≥96 ≥256 256 
Phase 256 ≥256 128 ≥96 ≥256 256 
NEX ≥1 ≥1 ≥1 1 ≥1 ≥1 
FOV 256mm 240mm 240mm 240mm 240mm 256mm 
























Up to 3xu Up to 2x Up to 2x Up to 2x Up to 2x Up to 3xu 
 
  
a 0.1 mmol/kg dose injection with a Gadolinium chelated contrast agent. Use of a power injector is 
desirable at an injection rate of 3-5cc/sec. (Note: If DSC perfusion is collected, contrast injection is 
performed after starting DSC acquisition. DSC perfusion can be performed with the “Ideal” protocol at 
3T as well as with the Minimum Standard protocols at 3T and 1.5T.)  
b Post-contrast 3D T1-weighted images should be collected with equivalent parameters to pre-contrast 3D 
T1-weighted images 
c TSE = turbo spin echo (Siemens & Philips) is equivalent to FSE (fast spin echo; GE, Hitachi, Toshiba) 
d FL2D = two-dimensional fast low angle shot (FLASH; Siemens) is equivalent to the spoil gradient 
recalled echo (SPGR; GE) or T1- fast field echo (FFE; Philips), fast field echo (FastFE; Toshiba), or the 
radiofrequency spoiled steady state acquisition rewound gradient echo (RSSG; Hitachi). A fast gradient 
echo sequence without inversion preparation is desired.  
e IR-GRE = inversion-recovery gradient-recalled echo sequence is equivalent to MPRAGE = 
magnetization prepared rapid gradient-echo (Siemens & Hitachi) and the inversion recovery spoiled 
gradient-echo (IR-SPGR or Fast SPGR with inversion activated or BRAVO; GE), 3D turbo field echo 
(TFE; Philips), or 3D fast field echo (3D Fast FE; Toshiba). 
f A 3D acquisition without inversion preparation will result in different contrast compared with MPRAGE 
or another IR-prepped 3D T1-weighted sequences and therefore should be avoided. 
g In the event of significant patient motion, a radial acquisition scheme may be used (e.g. BLADE 
[Siemens], PROPELLER [GE], MultiVane [Philips], RADAR [Hitachi], or JET [Toshiba]); however, this 
acquisition scheme is can cause significant differences in ADC quantification and therefore should be 
used only if EPI is not an option. Further, this type of acquisition takes considerable more time. 
h Dual echo PD/T2 TSE is optional for possible quantification of tissue T2. For this sequence, PD is 
recommended to have a TE < 25ms. 
i Advanced sequences can be substituted into this time slot, so long as 3D post-contrast T1-weighted 
images are collected between 4 and 8 min after contrast injection and this timing is constant across all MR 
exams performed in each patient.  
j 3D FLAIR is an optional alternative to 2D FLAIR, with sequence parameters as follows per EORTC 
guidelines: 3D TSE/FSE acquisition; TE=90-140ms; TR=6000-10000ms; TI=2000-2500ms (chosen 
based on vendor recommendations for optimized protocol and field strength); GRAPPA≤2; Fat 
Suppression; Slice thickness ≤ 1.5mm; Orientation Sagittal or Axial; FOV ≤ 250 mm x 250 mm; Matrix ≥ 
244x244. 
k Choice of TI should be chosen based on the magnetic field strength of the system (e.g. TI ≈ 2000ms for 
1.5T and TI ≈ 2500ms for 3T). 
l In order to ensure comparable SNR older 1.5T MR systems can use contiguous (no interslice gap) 
images with 5mm slice thickness or increase NEX for slice thickness ≤4mm. 
m For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TR = 5-15ms for 
similar contrast. 
n For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TI = 400-450ms for 
similar contrast.  
p Older model MR scanners that are not capable of >2 b-values should use b = 0 and 1000 s/mm2. 
q Axial 2D T2-weighted FLAIR and Axial 2D T2-weighted images can be interchanged pre- and post-
contrast.  
r Sites may choose to perform the 3D T1w IR-GRE sequence prior to the 2D T1w TSE/SE because of the 
potential risk of patient movement and to help with patient comfort. However, there is less inherent lesion 
conspicuity in the 3D T1w IR-GRE sequence, so delaying this sequence to the end may be efficacious. 
s Acceptable 3D T1w TSE sequences include CUBE (GE), SPACE (Siemens), VISTA (Philips), isoFSE 
(Hitachi), or 3D MVOX (Canon) 
t Flip angles for 3D TSE sequences (including CUBE and SPACE) are complicated because many utilize 
variable flip angle refocusing radiofrequency pulses to produce the desired image contrast. Investigators 
are encouraged to work with their scanner vendors to determine the ideal parameters.  
u Investigators are encouraged to work with their scanner vendors to determine the best parallel imaging 
strategies, which may include simultaneous multislice imaging (SMS), controlled aliasing in parallel 
imaging resulting in higher acceleration (CAIPI), iPAT, GRAPPA, as well as turbo or other acceleration 
factors.  
v While some sites may choose to collect DWI post-contrast, studies have suggested this can lower ADC 
measurements as much as 3% 152.  
Table 2: Minimum Standard 3T Metastatic Brain Tumor Imaging Protocol 
 


























Sequence IR-GREd,e,f TSEc SS-EPIg TSEc TSE/SE IR-GRE d,e,f 
Plane Sagittal or 
Axial 




Mode 3D 2D 2D 2D 2D 3D 
TR [ms] 2100m >6000 >5000 >2500 < 500 2100m 
TE [ms] Min 100-140 Min 80-120 Min Min 
TI [ms] 1100n 2000-2500k    1100n 
Flip Angle 10º-15º 90º/≥160º 90º/180º 90º/≥160º 90º/≥160º 10º-15º 
Frequency 256 ≥256 128 ≥256 ≥256 256 
Phase 256 ≥256 128 ≥256 ≥256 256 
NEX ≥1 ≥1 ≥1 ≥1 ≥1 ≥1 
FOV 256mm 240mm 240mm 240mm 240mm 256mm 
Slice Thickness 1mm 3mm 3mm 3mm 3mm 1mm 
Gap/Spacing 0 0 0 0 0 0 










Up to 3x t Up to 2x Up to 2x Up to 2x Up to 2x Up to 3x t 
 
  
a 0.1 mmol/kg dose injection with a Gadolinium chelated contrast agent. Use of a power injector is 
desirable at an injection rate of 3-5cc/sec. (Note: If DSC perfusion is collected, contrast injection is 
performed after starting DSC acquisition. DSC perfusion can be performed with the “Ideal” protocol at 
3T as well as with the Minimum Standard protocols at 3T and 1.5T.)  
b Post-contrast 3D T1-weighted images should be collected with equivalent parameters to pre-contrast 3D 
T1-weighted images 
c TSE = turbo spin echo (Siemens & Philips) is equivalent to FSE (fast spin echo; GE, Hitachi, Toshiba) 
d FL2D = two-dimensional fast low angle shot (FLASH; Siemens) is equivalent to the spoil gradient 
recalled echo (SPGR; GE) or T1- fast field echo (FFE; Philips), fast field echo (FastFE; Toshiba), or the 
radiofrequency spoiled steady state acquisition rewound gradient echo (RSSG; Hitachi). A fast gradient 
echo sequence without inversion preparation is desired.  
e IR-GRE = inversion-recovery gradient-recalled echo sequence is equivalent to MPRAGE = 
magnetization prepared rapid gradient-echo (Siemens & Hitachi) and the inversion recovery spoiled 
gradient-echo (IR-SPGR or Fast SPGR with inversion activated or BRAVO; GE), 3D turbo field echo 
(TFE; Philips), or 3D fast field echo (3D Fast FE; Toshiba). 
f A 3D acquisition without inversion preparation will result in different contrast compared with MPRAGE 
or another IR-prepped 3D T1-weighted sequences and therefore should be avoided. 
g In the event of significant patient motion, a radial acquisition scheme may be used (e.g. BLADE 
[Siemens], PROPELLER [GE], MultiVane [Philips], RADAR [Hitachi], or JET [Toshiba]); however, this 
acquisition scheme is can cause significant differences in ADC quantification and therefore should be 
used only if EPI is not an option. Further, this type of acquisition takes considerable more time. 
h Dual echo PD/T2 TSE is optional for possible quantification of tissue T2. For this sequence, PD is 
recommended to have a TE < 25ms. 
i Advanced sequences can be substituted into this time slot, so long as 3D post-contrast T1-weighted 
images are collected between 4 and 8 min after contrast injection.  
j 3D FLAIR is an optional alternative to 2D FLAIR, with sequence parameters as follows per EORTC 
guidelines: 3D TSE/FSE acquisition; TE=90-140ms; TR=6000-10000ms; TI=2000-2500ms (chosen 
based on vendor recommendations for optimized protocol and field strength); GRAPPA≤2; Fat 
Suppression; Slice thickness ≤ 1.5mm; Orientation Sagittal or Axial; FOV ≤ 250 mm x 250 mm; Matrix ≥ 
244x244. 
k Choice of TI should be chosen based on the magnetic field strength of the system (e.g. TI ≈ 2000ms for 
1.5T and TI ≈ 2500ms for 3T). 
l In order to ensure comparable SNR older 1.5T MR systems can use contiguous (no interslice gap) 
images with 5mm slice thickness or increase NEX for slice thickness ≤4mm. 
m For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TR = 5-15ms for 
similar contrast. 
n For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TI = 400-450ms for 
similar contrast.  
p Older model MR scanners that are not capable of >2 b-values should use b = 0 and 1000 s/mm2. 
q Axial 2D T2-weighted FLAIR and Axial 2D T2-weighted images can be interchanged pre- and post-
contrast.  
r Sites may choose to perform the 3D T1w IR-GRE sequence prior to the 2D T1w TSE/SE because of the 
potential risk of patient movement and to help with patient comfort. However, there is less inherent lesion 
conspicuity in the 3D T1w IR-GRE sequence, so delaying this sequence to the end may be efficacious. 
s Adding FLAIR to this T1-weighted imaging at 3T could be considered for CSF suppression.  
t Investigators are encouraged to work with their scanner vendors to determine the best parallel imaging 
strategies, which may include simultaneous multislice imaging (SMS), controlled aliasing in parallel 
imging resulting in higher acceleration (CAIPI), iPAT, GRAPPA, as well as turbo or other acceleration 
factors.  
u While some sites may choose to collect DWI post-contrast, studies have suggested this can lower ADC 





Table 3: Minimum Standard 1.5T Metastatic Brain Tumor Imaging Protocol 
 


























Sequence IR-GRE d,e,f TSEc SS-EPIg TSEc TSE/SE IR-GRE d,e,f 
Plane Sagittal or 
Axial 




Mode 3D 2D 2D 2D 2D 3D 
TR [ms] 2100m >6000 >5000 >3500 400-600 2100m 
TE [ms] Min 100-140 Min 80-120 Min Min 
TI [ms] 1100n 2000-2500k    1100n 
Flip Angle 10º-15º 90º/≥160º 90º/180º 90º/≥160º 90º/≥160º 10º-15º 
Frequency ≥172 ≥256 128 ≥256 ≥256 ≥172 
Phase ≥172 ≥256 128 ≥256 ≥256 ≥172 
NEX ≥1 ≥1 ≥1 ≥1 ≥1 ≥1 
FOV 256mm 240mm 240mm 240mm 240mm 256mm 
Slice Thickness ≤1.5mm ≤4mml ≤4mml ≤4mml ≤4mml ≤1.5mm 
Gap/Spacing 0 0 0 0 0 0 










Up to 2xs Up to 2x Up to 2x Up to 2x Up to 2x Up to 2xs 
 
  
a 0.1 mmol/kg dose injection with a Gadolinium chelated contrast agent. Use of a power injector is 
desirable at an injection rate of 3-5cc/sec. (Note: If DSC perfusion is collected, contrast injection is 
performed after starting DSC acquisition)  
b Post-contrast 3D T1-weighted images should be collected with equivalent parameters to pre-contrast 3D 
T1-weighted images 
c TSE = turbo spin echo (Siemens & Philips) is equivalent to FSE (fast spin echo; GE, Hitachi, Toshiba) 
d FL2D = two-dimensional fast low angle shot (FLASH; Siemens) is equivalent to the spoil gradient 
recalled echo (SPGR; GE) or T1- fast field echo (FFE; Philips), fast field echo (FastFE; Toshiba), or the 
radiofrequency spoiled steady state acquisition rewound gradient echo (RSSG; Hitachi). A fast gradient 
echo sequence without inversion preparation is desired.  
e IR-GRE = inversion-recovery gradient-recalled echo sequence is equivalent to MPRAGE = 
magnetization prepared rapid gradient-echo (Siemens & Hitachi) and the inversion recovery spoiled 
gradient-echo (IR-SPGR or Fast SPGR with inversion activated or BRAVO; GE), 3D turbo field echo 
(TFE; Philips), or 3D fast field echo (3D Fast FE; Toshiba). 
f A 3D acquisition without inversion preparation will result in different contrast compared with MPRAGE 
or another IR-prepped 3D T1-weighted sequences and therefore should be avoided. 
g In the event of significant patient motion, a radial acquisition scheme may be used (e.g. BLADE 
[Siemens], PROPELLER [GE], MultiVane [Philips], RADAR [Hitachi], or JET [Toshiba]); however, this 
acquisition scheme is can cause significant differences in ADC quantification and therefore should be 
used only if EPI is not an option. Further, this type of acquisition takes considerable more time. 
h Dual echo PD/T2 TSE is optional for possible quantification of tissue T2. For this sequence, PD is 
recommended to have a TE < 25ms. 
i Advanced sequences can be substituted into this time slot, so long as 3D post-contrast T1-weighted 
images are collected between 4 and 8 min after contrast injection.  
j 3D FLAIR is an optional alternative to 2D FLAIR, with sequence parameters as follows per EORTC 
guidelines: 3D TSE/FSE acquisition; TE=90-140ms; TR=6000-10000ms; TI=2000-2500ms (chosen 
based on vendor recommendations for optimized protocol and field strength); GRAPPA≤2; Fat 
Suppression; Slice thickness ≤ 1.5mm; Orientation Sagittal or Axial; FOV ≤ 250 mm x 250 mm; Matrix ≥ 
244x244. 
k Choice of TI should be chosen based on the magnetic field strength of the system (e.g. TI ≈ 2000ms for 
1.5T and TI ≈ 2500ms for 3T). 
l In order to ensure comparable SNR older 1.5T MR systems can use contiguous (no interslice gap) 
images with 5mm slice thickness or increase NEX for slice thickness ≤4mm. 
m For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TR = 5-15ms for 
similar contrast. 
n For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TI = 400-450ms for 
similar contrast.  
p Older model MR scanners that are not capable of >2 b-values should use b = 0 and 1000 s/mm2. 
q Axial 2D T2-weighted FLAIR and Axial 2D T2-weighted images can be interchanged pre- and post-
contrast.  
r Sites may choose to perform the 3D T1w IR-GRE sequence prior to the 2D T1w TSE/SE because of the 
potential risk of patient movement and to help with patient comfort. However, there is less inherent lesion 
conspicuity in the 3D T1w IR-GRE sequence, so delaying this sequence to the end may be efficacious. 
s Investigators are encouraged to work with their scanner vendors to determine the best parallel imaging 
strategies, which may include simultaneous multislice imaging (SMS), controlled aliasing in parallel 
imging resulting in higher acceleration (CAIPI), iPAT, GRAPPA, as well as turbo or other acceleration 
factors.  
t While some sites may choose to collect DWI post-contrast, studies have suggested this can lower ADC 
measurements as much as 3% 152.  
 
